Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties.

Yakovenko ML, Cherkasova EA, Rezapkin GV, Ivanova OE, Ivanov AP, Eremeeva TP, Baykova OY, Chumakov KM, Agol VI.

J Virol. 2006 Mar;80(6):2641-53.

2.

Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel.

Shulman LM, Manor Y, Handsher R, Delpeyroux F, McDonough MJ, Halmut T, Silberstein I, Alfandari J, Quay J, Fisher T, Robinov J, Kew OM, Crainic R, Mendelson E.

J Clin Microbiol. 2000 Oct;38(10):3729-34.

3.

Determination of antigenic properties of vaccine derived poliovirus strains.

Pliaka V, Achilleos C, Kyriakopoulou Z, Tsakogiannis D, Ruether IG, Gartzonica C, Levidiotou-Stefanou S, Markoulatos P.

Vaccine. 2010 Dec 10;29(1):26-33. doi: 10.1016/j.vaccine.2010.10.028. Epub 2010 Oct 23.

PMID:
20974307
4.

Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013.

Shulman LM, Martin J, Sofer D, Burns CC, Manor Y, Hindiyeh M, Gavrilin E, Wilton T, Moran-Gilad J, Gamzo R, Mendelson E, Grotto I; GPI (Genotype–Phenotype Identification) Group; GPI Genotype-Phenotype Identification Group.

Clin Infect Dis. 2015 Apr 1;60(7):1057-64. doi: 10.1093/cid/ciu1136. Epub 2014 Dec 30.

PMID:
25550350
5.

Determinants of monovalent oral polio vaccine mutagenesis in vaccinated elderly people.

Boot HJ, Sonsma J, van Nunen F, Abbink F, Kimman TG, Buisman AM.

Vaccine. 2007 Jun 11;25(24):4706-14. Epub 2007 Apr 20.

PMID:
17482726
6.

Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.

Blomqvist S, Savolainen C, Laine P, Hirttiö P, Lamminsalo E, Penttilä E, Jöks S, Roivainen M, Hovi T.

J Virol. 2004 May;78(9):4876-83.

7.

Retrospective molecular and phenotypic analysis of poliovirus vaccine strains isolated in Greece.

Pliaka V, Filliponi ME, Kyriakopoulou Z, Ruether IG, Tsakogiannis D, Gartzonika C, Levidiotou-Stefanou S, Markoulatos P.

Clin Microbiol Infect. 2011 Oct;17(10):1554-62. doi: 10.1111/j.1469-0691.2011.03470.x. Epub 2011 Mar 7.

8.

Long-term excretion of vaccine-derived poliovirus by a healthy child.

Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, Cooper G, Fitzharris C, Butler K, Hall WW, Minor PD.

J Virol. 2004 Dec;78(24):13839-47.

9.

Evolution of the Sabin vaccine into pathogenic derivatives without appreciable changes in antigenic properties: need for improvement of current poliovirus surveillance.

Yakovenko ML, Korotkova EA, Ivanova OE, Eremeeva TP, Samoilovich E, Uhova I, Gavrilin GV, Agol VI.

J Virol. 2009 Apr;83(7):3402-6. doi: 10.1128/JVI.02122-08. Epub 2009 Jan 7.

10.

Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Minor PD, Ferguson M, Evans DM, Almond JW, Icenogle JP.

J Gen Virol. 1986 Jul;67 ( Pt 7):1283-91.

PMID:
2425046
11.

Oral poliovaccine: will it help eradicate polio or cause the next epidemic?

Shulman LM, Manor Y, Sofer D, Swartz T, Mendelson E.

Isr Med Assoc J. 2006 May;8(5):312-5.

12.

Mapping of type 1 poliovirus neutralization epitopes.

Blondel B, Crainic R, Dufraisse G, Candréa A, Horaud F.

Dev Biol Stand. 1985;60:337-42.

PMID:
2412917
13.
14.

Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.

Osterhaus AD, van Wezel AL, van Steenis B, Drost GA, Hazendonk TG.

Intervirology. 1981;16(4):218-24.

PMID:
6177658
15.

Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.

Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ, Lee HC, Huang YC, Lin TY, Chen PJ, Shimizu H, Nishimura Y, Utama A, Pallansch M, Miyamura T, Kew O, Yang JY.

J Virol. 2005 Oct;79(20):12623-34.

16.

Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient.

Odoom JK, Yunus Z, Dunn G, Minor PD, Martín J.

J Virol. 2008 Sep;82(18):9179-90. doi: 10.1128/JVI.00468-08. Epub 2008 Jul 2.

17.

Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Shaw J, Jorba J, Zhao K, Iber J, Chen Q, Adu F, Adeniji A, Bukbuk D, Baba M, Henderson E, Dybdahl-Sissoko N, McDonald S, Weldon WC, Gumede N, Oberste MS, Kew OM, Burns CC.

J Virol. 2018 Apr 13;92(9). pii: e01949-17. doi: 10.1128/JVI.01949-17. Print 2018 May 1.

18.

Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.

Horie H, Yoshida H, Matsuura K, Miyazawa M, Wakabayashi K, Nomoto A, Hashizume S.

J Med Virol. 2002 Nov;68(3):445-51.

PMID:
12226835
19.

Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.

Minor PD, Ferguson M, Katrak K, Wood D, John A, Howlett J, Dunn G, Burke K, Almond JW.

J Gen Virol. 1990 Nov;71 ( Pt 11):2543-51.

PMID:
1701474

Supplemental Content

Support Center